Literature DB >> 6588384

Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy.

I Singh, A E Moser, S Goldfischer, H W Moser.   

Abstract

The deficient oxidation and accumulation of very-long-chain fatty acids in the Zellweger cerebro-hepato-renal syndrome (CHRS) and X chromosome-linked adrenoleukodystrophy (ALD), coupled with the observation that peroxisomes are lacking in CHRS, prompted us to investigate the subcellular localization of the catabolism of lignoceric acid (C24:0). Peroxisomal and mitochondrial-rich fractions were separated from rat liver crude mitochondria by sucrose density gradient centrifugation. Enzyme activity for the oxidation of [1-14C]palmitic acid to water-soluble acetate was 2- to 3-fold higher in the mitochondrial than in the peroxisomal-rich fraction whereas [1-14C]lignoceric acid was oxidized at a 2- to 3-fold higher rate in the peroxisomal than in the mitochondrial fraction. Moreover, unlike palmitic acid oxidation, lignoceric acid oxidation was not inhibited by potassium cyanide in either rat liver fractions or human skin cultured fibroblasts, showing that lignoceric acid is mainly and possibly exclusively oxidized in peroxisomes. We also conducted studies to clarify the striking phenotypic differences between CHRS and the childhood form of ALD. In contrast to CHRS, we found normal hepatocellular peroxisomes in the liver biopsy of a childhood ALD patient. In addition, in the presence of potassium cyanide, the oxidation of palmitic acid in cultured skin fibroblasts was inhibited by 62% in control and X chromosome-linked ALD patients compared with 88% in CHRS and neonatal ALD. This differential effect may be related to differences in peroxisomal morphology in those disorders.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6588384      PMCID: PMC345397          DOI: 10.1073/pnas.81.13.4203

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Cerebro-hepato-renal syndrome of Zellweger. A report of eight cases with comments upon the incidence, the liver lesion, and a fault in pipecolic acid metabolism.

Authors:  D M Danks; P Tippett; C Adams; P Campbell
Journal:  J Pediatr       Date:  1975-03       Impact factor: 4.406

2.  Adrenoleukodystrophy. A clinical and pathological study of 17 cases.

Authors:  H H Schaumburg; J M Powers; C S Raine; K Suzuki; E P Richardson
Journal:  Arch Neurol       Date:  1975-09

3.  The evaluation of infants with the Zellweger (cerebro-hepato-renal) syndrome.

Authors:  K W Gilchrist; E F Gilbert; N T Shahidi; J M Opitz
Journal:  Clin Genet       Date:  1975 May-Jun       Impact factor: 4.438

4.  A new method for simultaneous purification of cytochrome b5 and NADPH-cytochrome c reductase from rat liver microsomes.

Authors:  T Omura; S Takesue
Journal:  J Biochem       Date:  1970-02       Impact factor: 3.387

5.  Cerebro-hepato-renal syndrome. A newly recognized hereditary disorder of multiple congenital defects, including sudanophilic leukodystrophy, cirrhosis of the liver, and polycystic kidneys.

Authors:  E Passarge; A J McAdams
Journal:  J Pediatr       Date:  1967-11       Impact factor: 4.406

6.  Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome.

Authors:  S Goldfischer; C L Moore; A B Johnson; A J Spiro; M P Valsamis; H K Wisniewski; R H Ritch; W T Norton; I Rapin; L M Gartner
Journal:  Science       Date:  1973-10-05       Impact factor: 47.728

7.  Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration.

Authors:  J J Volpe; R D Adams
Journal:  Acta Neuropathol       Date:  1972       Impact factor: 17.088

8.  Synthesis of cerebronic acid from lignoceric acid by rat brain preparation. Some properties and distribution of the -hydroxylation system.

Authors:  M Hoshi; Y Kishimoto
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

9.  A metabolic disorder similar to Zellweger syndrome with hepatic acatalasia and absence of peroxisomes, altered content and redox state of cytochromes, and infantile cirrhosis with hemosiderosis.

Authors:  H T Versmold; H J Bremer; V Herzog; G Siegel; D B Bassewitz; U Irle; H Voss; I Lombeck; B Brauser
Journal:  Eur J Pediatr       Date:  1977-03-18       Impact factor: 3.183

10.  The large-scale separation of peroxisomes, mitochondria, and lysosomes from the livers of rats injected with triton WR-1339. Improved isolation procedures, automated analysis, biochemical and morphological properties of fractions.

Authors:  F Leighton; B Poole; H Beaufay; P Baudhuin; J W Coffey; S Fowler; C De Duve
Journal:  J Cell Biol       Date:  1968-05       Impact factor: 10.539

View more
  88 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Isolation and biochemical characterization of peroxisomes from cultured rat glial cells.

Authors:  I Singh; O Carillo; A Namboodiri
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

Review 3.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

4.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 5.  Peroxisomal disorders: clinical, biochemical, and molecular aspects.

Authors:  R J Wanders
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 6.  X-linked adrenoleukodystrophy: genes, mutations, and phenotypes.

Authors:  K D Smith; S Kemp; L T Braiterman; J F Lu; H M Wei; M Geraghty; G Stetten; J S Bergin; J Pevsner; P A Watkins
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 7.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

8.  A missense point mutation (Ser515Phe) in the adrenoleukodystrophy gene in a family with adrenomyeloneuropathy: a clinical, biochemical, and genetic study.

Authors:  M Vorgerd; S Fuchs; M Tegenthoff; J P Malin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

9.  Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts.

Authors:  N Cartier; J Lopez; P Moullier; F Rocchiccioli; M O Rolland; P Jorge; J Mosser; J L Mandel; P F Bougnères; O Danos
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Adrenoleukodystrophy without adrenal insufficiency and its magnetic resonance imaging.

Authors:  H Nishio; S Kodama; T Tsubota; T Takumi; T Takahashi; S Yokoyama; T Matsuo
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.